Acadia Pharmaceuticals Job Trends

Acadia Pharmaceuticals logo
1
Active Jobs (Last 14 Days)
0
Fresh Jobs (Last 3 Days)
100%
Jobs with Salary Data

Recent Job Posting Activity (30 Days)

Acadia Pharmaceuticals 30-day hiring trend

Job Category Distribution

Acadia Pharmaceuticals job category distribution
Data spans Jun 14, 2025 through Jul 14, 2025, aggregated by PharmaPayWatch.com. Recent job postings shows the number of jobs posted each day (bars) for the past 30 days with an overlay of the 7 day running average. The rose plot shows how PharmaPayWatch categorizes those jobs to get a better sense of Acadia Pharmaceuticals's recent hiring focus. Note that some jobs aren't categorized by our filters, we exclude those from the rose plot.

Current Acadia Pharmaceuticals Jobs, Salary Data, and Stats

In the last two weeks, Acadia Pharmaceuticals has posted 1 positions. None of those roles offer remote or hybrid work. We've been tracking Acadia Pharmaceuticals since February 25, 2025.

Career Tracks Currently Hiring

Commercial Other Scientific Research Quality & Regulatory Medical Affairs Manufacturing Data Science Software & IT

Currently Hiring Office Locations

San Diego, California, United States United States - Remote Missouri - Remote Princeton, New Jersey, United States Tennessee - Remote and 39 more

Current Acadia Pharmaceuticals Jobs

Last updated: Jul 14, 2025

Showing 1 active jobs. Active jobs were posted in the last 14 days. Fresh jobs were posted within the last 3 days. Click a row for more details.

Role

Senior Director, Translational Sciences

Jul 3
$234,000 - $292,200
Princeton, New Jersey, United States; San Diego, California, United States; San Francisco, California
Apply →
About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis, and multiple other programs targeting neuro-psychiatric and neuro-rare diseases. For more information, visit Acadia.com and...